EX-10.1



 Exhibit 10.1 

Execution Copy 

$400,000,000 
 RINGCENTRAL,
INC. 
 0% CONVERTIBLE SENIOR NOTES DUE 2023 

PURCHASE AGREEMENT 
 February 28, 2018 







 February 28, 2018 

Morgan Stanley & Co. LLC 
 Goldman Sachs & Co.
LLC 
 As “Representatives” of the several 

Initial Purchasers named 
 in
Schedule I hereto 
 c/o Morgan Stanley & Co. LLC 

1585 Broadway 
 New York, New York
10036 
 c/o Goldman Sachs & Co. LLC, 

200 West Street, 
 New York, New
York 10282-2198 
 Ladies and Gentlemen: 

RingCentral, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several purchasers named in
Schedule I hereto (the “Initial Purchasers”) $400,000,000 principal amount of its 0% Convertible Senior Notes due 2023 (the “Firm Securities”) to be issued pursuant to the provisions of an Indenture
dated on or about March 5, 2018 (the “Indenture”) between the Company and U.S. Bank National Association, as Trustee (the “Trustee”). The Company also proposes to issue and sell to the Initial Purchasers not
more than an additional $60,000,000 principal amount of its 0% Convertible Senior Notes due 2023 (the “Additional Securities”) if and to the extent that you, as the Representatives of the offering, shall have determined to exercise,
on behalf of the Initial Purchasers, the right to purchase such 0% Convertible Senior Notes due 2023 granted to the Initial Purchasers in Section 2 hereof. The Firm Securities and the Additional Securities are hereinafter collectively referred
to as the “Securities”. The Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), is hereinafter referred to herein as the
“Class A Common Stock”. The Securities will be convertible into cash, shares of Class A Common Stock (the “Underlying Securities”), or a combination of cash and Underlying Securities, at the
Company’s election in accordance with the terms of the Indenture. 
 The Securities and the Underlying Securities will be offered
without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to qualified institutional buyers in compliance with the exemption from registration provided by Rule 144A under the Securities Act. In
connection with the sale of the Securities, the Company has prepared a preliminary offering memorandum (the “Preliminary Memorandum”) and will prepare a final offering memorandum (the “Final Memorandum”) including
or incorporating by reference a description of the terms of the Securities and the Underlying Securities, the terms of the offering and a description of the Company. For purposes of this Agreement, “Additional Written 








 
Offering Communication” means any written communication (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or a solicitation of an offer to buy the
Securities other than the Preliminary Memorandum or the Final Memorandum; “Time of Sale Memorandum” means the Preliminary Memorandum together with each Additional Written Offering Communication or other information, if any, each
identified in Schedule II hereto under the caption Time of Sale Memorandum; and “General Solicitation” means any offer to sell or solicitation of an offer to buy the Securities by any form of general solicitation or advertising
(as those terms are used in Regulation D under the Securities Act). As used herein, the terms Preliminary Memorandum, Time of Sale Memorandum and Final Memorandum shall include the documents, if any, incorporated by reference therein on the date
hereof. The terms “supplement”, “amendment” and “amend” as used herein with respect to the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum or any Additional Written
Offering Communication shall include all documents subsequently filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), that are deemed to be incorporated by reference therein. 
 1.    Representations and
Warranties. The Company represents and warrants to, and agrees with, the Representatives that: 

(a)    (i) Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by
reference in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder,
(ii) the Time of Sale Memorandum does not, and at the time of each sale of the Securities in connection with the offering when the Final Memorandum is not yet available to prospective purchasers and at the Closing Date (as defined in
Section 4), the Time of Sale Memorandum, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading, (iii) any Additional Written Offering Communication prepared, used or referred to by the Company, when considered together with the Time of Sale Memorandum, at the time of
its use did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (iv) any General
Solicitation that is not an Additional Written Offering Communication, made by the Company or by an Initial Purchaser with the consent of the Company, when considered together with the Time of Sale Memorandum, at the time when made or used did not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (v) the Preliminary Memorandum does not
contain and the Final Memorandum, in the form used by the Initial Purchasers to confirm sales and on the Closing Date (as defined in Section 4), will not contain any untrue statement of a material fact or


  
 2 








 
omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and
warranties set forth in this paragraph do not apply to statements or omissions in the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, Additional Written Offering Communication or General Solicitation based upon information
relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use therein. 

(b)    Except for the Additional Written Offering Communications, if any, identified in Schedule II
hereto, including electronic road shows, if any, furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the Representatives’ prior consent, prepare, use or refer to, any
Additional Written Offering Communication. 
 (c)    Neither the Company nor any of its subsidiaries has
sustained since the date of the latest audited financial statements included in the Time of Sale Memorandum any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or
from any labor dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Time of Sale Memorandum and the Final Memorandum; and, since the respective dates as of which information is given in the
Time of Sale Memorandum and the Final Memorandum, there has not been any change in the capital stock (other than (A) as a result of the exercise of stock options or the award of stock options, restricted stock or restricted stock units in the
ordinary course of business pursuant to the Company’s stock plans that are described in the Time of Sale Memorandum and the Final Memorandum, (B) the repurchase of shares of capital stock that were issued pursuant to the early exercise of
stock options by option holders and are subject to repurchase by the Company, or (C) the exercise of warrants to purchase shares of capital stock on or before the date of this Agreement where such warrants were described in the Time of Sale
Memorandum and the Final Memorandum) or long-term debt of the Company or any of its subsidiaries or any material adverse change, or any development involving a prospective material adverse change, in or affecting the general affairs, management,
financial position, stockholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”), otherwise than as set forth or contemplated in the Time of Sale Memorandum
and the Final Memorandum. 
 (d)    The Company has been duly incorporated, is validly existing as a
corporation in good standing under the laws of the State of Delaware, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Memorandum and is duly qualified to transact business and is
in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not, individually
or in the aggregate, have a Material Adverse Effect. 

  
 3 








 (e)    Each subsidiary of the Company has been duly
incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale
Memorandum and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be
so qualified or be in good standing would not, individually or in the aggregate have a Material Adverse Effect; all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully
paid and non-assessable and are owned directly by the Company, free and clear of all liens, encumbrances, equities or claims. 

(f)    This Agreement has been duly authorized, executed and delivered by the Company. 

(g)    The Company has an authorized capitalization as set forth in the Time of Sale Memorandum and the
Final Memorandum, and all of the issued shares of capital stock of the Company, including the Class A Common Stock and the Company’s Class B common stock, par value $0.0001 per share (the “Class B Common
Stock” and, together with the Class A Common Stock, the “Common Stock”), have been duly and validly authorized and issued and are fully paid and non-assessable and conform to the
description of such capital stock contained in the Time of Sale Memorandum and the Final Memorandum. 

(h)    The Securities have been duly authorized and, when executed and authenticated in accordance with the
provisions of the Indenture and delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, will be valid and binding obligations of the Company, enforceable in accordance with their terms, subject to
(A) applicable bankruptcy, insolvency, fraudulent conveyance, fraudulent transfer, reorganization, moratorium or similar laws affecting creditors’ rights generally and (B) equitable principles of general applicability, (including,
without limitation, concepts of materiality, reasonableness, good faith and fair dealing, regardless of whether enforcement is considered at law or in equity)(together, the “Enforceability Exceptions”), and will be entitled to the
benefits of the Indenture pursuant to which such Securities are to be issued. 
 (i)     The maximum
number of Underlying Securities initially issuable upon conversion of the Securities (including the maximum number of additional Underlying Securities by which the Conversion Rate (as such term is defined in the Time of Sale Memorandum and the Final
Memorandum) (the “Conversion Rate”) may be increased in connection with a make-whole fundamental change (as such term is defined in the Time of Sale Memorandum and the Final Memorandum) and assuming (x) the Company elects, upon
each conversion of the Securities, to deliver solely shares of Common Stock, other than cash in lieu of fractional shares, in settlement of each conversion and (y) the Initial Purchasers 

  
 4 








 
exercise their option to purchase the Additional Securities in full (the “Maximum Number of Underlying Securities”)) have been duly authorized and reserved and, when issued upon
conversion of the Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non-assessable, and the issuance of the Underlying Securities will not be subject to any
preemptive or similar rights. 
 (j)    The Indenture has been duly authorized by the Company and, when
executed and delivered by the Company and the Trustee, the Indenture will be a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. 

(k)    The execution and delivery by the Company of, and the performance by the Company of its obligations
under, this Agreement, the Indenture, and the Securities (collectively, the “Transaction Documents”) will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under (as
applicable), (1) any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of
the property or assets of the Company or any of its subsidiaries is subject, (2) the Certificate of Incorporation or By-laws or similar organizational documents of the Company or any of its subsidiaries
or any statute or (3) any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, except in the case of (1) and (3) for such as would
not individually or in the aggregate have a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the execution and delivery by
the Company of, and the performance by the Company of its obligations under, the Transaction Documents, except such consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in
connection with the purchase and distribution of the Securities by the Initial Purchasers or where the failure to obtain any such consent, approval, authorization, order, registration or qualification would not individually or in the aggregate
reasonably be expected to have a Material Adverse Effect or impede the ability of the Company to consummate the transactions contemplated by the Transaction Documents. 

(l)    Neither the Company nor any of its subsidiaries is, of after notice or lapse of time or both, will
be, in violation of (1) its Certificate of Incorporation or By-laws or similar organizational documents or (2) any other statute or any order, rule or regulation of any court or governmental agency
or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, or in default in the performance or observance of any material obligation, agreement, covenant or condition contained in any indenture, mortgage,
deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound except in the case of (2) for such violations as would not individually or in the aggregate have a
Material Adverse Effect. 

  
 5 








 (m)    The statements set forth in the Time of Sale
Memorandum and the Final Memorandum under the caption “Description of Capital Stock”, insofar as they purport to constitute a summary of the terms of the Company’s capital stock, under the caption “Certain United States Federal
Income Tax Considerations, and under the caption “Plan of Distribution”, insofar as they purport to describe the provisions of the laws and documents referred to therein, are fairly summarized in all material respects. 

(n)    KPMG LLP, who have certified certain financial statements of the Company and its subsidiaries, are
independent public accountants as required by the Securities Act and the rules and regulations of the Commission thereunder. KPMG LLP, who have certified certain financial statements of the Company and its subsidiaries, were independent public
accountants as required the Securities Act and the rules and regulations of the Commission thereunder with respect to the Company and its subsidiaries as of the date of its report incorporated by reference in the Time of Sale Memorandum and the
Final Memorandum. 
 (o)    Other than as set forth in the Time of Sale Memorandum, there are no legal or
governmental proceedings pending to which the Company or any of its subsidiaries or of which any property or assets of the Company or any of its subsidiaries is the subject which would individually or in the aggregate have a Material Adverse Effect
or have a material adverse effect on the ability of the Company to perform its obligations under the Transaction Documents or to consummate the transactions contemplated by the Time of Sale Information and the Final Memorandum; and, to the
Company’s knowledge, no such proceedings are threatened or contemplated by governmental authorities or by others. 

(p)    The Company and its subsidiaries (i) are in compliance with any and all applicable foreign,
federal, state, provincial and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances, wastes or materials, pollutants or contaminants (“Environmental
Laws”), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such
permit, license or approval, except where such non-compliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of
such permits, licenses or approvals would not individually or in the aggregate have a Material Adverse Effect. 

(q)    The Company is not, and after giving effect to the offering and sale of the Securities and the
application of the proceeds thereof will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”). 

  
 6 








 (r)    Neither the Company nor any affiliate (as defined in
Rule 501(b) of Regulation D under the Securities Act, an “Affiliate”) of the Company has directly, or through any agent, (i) sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any
security (as defined in the Securities Act) which is or will be integrated with the sale of the Securities in a manner that would require the registration under the Securities Act of the Securities, (ii) made any General Solicitation that is
not an Additional Written Offering Communication other than General Solicitations listed on Schedule II hereto or those made with the prior written consent of Morgan Stanley & Co. LLC, or (iii) offered, solicited offers to buy or sold
the Securities in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act. 

(s)    It is not necessary in connection with the offer, sale and delivery of the Securities to the Initial
Purchasers in the manner contemplated by this Agreement to register the Securities under the Securities Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended. 

(t)    The Securities satisfy the requirements set forth in Rule 144A(d)(3) under the Securities Act.

 (u)    Neither the Company nor any of its subsidiaries or controlled affiliates, nor, to the
Company’s knowledge, any director, officer or employee, nor, to the Company’s knowledge, any agent or representative of the Company or of any of its subsidiaries or controlled affiliates, has taken or will take any action in furtherance of
an offer, payment, promise to pay, or authorization or approval of the payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any “government official” (including any officer or employee of a
government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political
office) to influence official action or secure an improper advantage; and the Company and its subsidiaries and controlled affiliates have conducted their businesses in compliance with applicable anti-corruption laws, including the Foreign Corrupt
Practices Act of 1977. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and
anti-corruption laws. Neither the Company nor its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else
of value, to any person in violation of any applicable anti-bribery and anti-corruption laws. 

(v)    The operations of the Company and its subsidiaries are and have been conducted at all times in
compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and
Obstruct Terrorism Act of 

  
 7 








 
2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder and any
related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. 

(w)    Neither the Company nor any of its subsidiaries, nor, to the Company’s knowledge, any director,
officer, agent, controlled affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (“Person”) that is the subject or target of any sanctions administered or enforced by the U.S. Department
of the Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively,
“Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea and Syria). 

(x)    The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or
facilitation, is the subject of Sanctions; or in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). 

(y)    For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now
knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. 

(z)    The Company and each of its subsidiaries have filed all federal, state, local and foreign tax
returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not individually or in the aggregate have a Material Adverse Effect) and have paid all taxes required to be
paid thereon (except for cases in which the failure to file or pay would not have a material adverse effect on the current or future financial position, stockholders’ equity or results of operations of the Company and its subsidiaries, or,
except as currently being contested in good faith and for which reserves required by generally accepted accounting principles as applied in the United States (“U.S. GAAP”) have been created in the financial statements of the
Company), and no tax deficiency has been determined adversely to the Company or any of its subsidiaries which has had (nor does the Company 

  
 8 








 
nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its subsidiaries and which could
reasonably be expected to have) a material adverse effect on the current or future financial position, stockholders’ equity or results of operations of the Company and its subsidiaries. 

(aa)    The Company and each of its subsidiaries maintains a system of internal control over financial
reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that complies with the requirements of the Exchange Act and has
been designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles and that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific
authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as set forth in the Time of Sale Memorandum, the
Company’s internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting. 

(bb)    Since the date of the latest audited financial statements incorporated by reference in this Time of
Sale Memorandum and the Final Memorandum, there has been no change in the Company’s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the
Company’s internal control over financial reporting. 
 (cc)    The financial statements of the
Company filed with the Commission and included in the Company’s annual report on Form 10-K for the year ended December 31, 2017 (the “2017
10-K”), which is incorporated by reference into the Time of Sale Memorandum and the Final Memorandum, present fairly in all material respects the financial position of the Company as of the dates
indicated and the results of its operations and cash flows for the periods specified. Such financial statements have been prepared in all material respects in conformity with U.S. GAAP applied on a consistent basis throughout the periods involved;
and the selected financial data included in the 2017 10-K, which is incorporated by reference into the Time of Sale Memorandum and the Final Memorandum, present fairly in all material respects the information
shown therein and have been compiled on a basis consistent with that of the financial statements included in the 2017 10-K, which is incorporated by reference into the Time of Sale Memorandum and the Final
Memorandum; 

  
 9 








 (dd)    The Company maintains disclosure controls and
procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that
material information relating to the Company and its subsidiaries is made known to the Company’s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are
effective. 
 (ee)    The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and
guidelines applicable thereto. 
 (ff)    The Company and its subsidiaries own or possess or can obtain
on commercially reasonable terms licenses to all trademarks, service marks, trade names, trade dress, domain names (including all goodwill associated with the foregoing), patents, inventions, copyrights, software,
know-how, trade secrets (including all registrations and applications for registration of any of the foregoing), publicity rights, privacy rights and all other similar types of proprietary intellectual
property rights (collectively, “Intellectual Property”) necessary to the conduct of their respective businesses as conducted, as described in the Time of Sale Memorandum and the Final Memorandum, except where the failure to have any
of the foregoing would not reasonably be expected to have a Material Adverse Effect. Except as described in the Time of Sale Memorandum and the Final Memorandum, to the knowledge of the Company, the conduct of their respective businesses does not
infringe, misappropriate or otherwise conflict with any Intellectual Property rights of others. Neither the Company nor any of its subsidiaries has received any written notice of any claim of infringement, misappropriation or conflict with any
Intellectual Property rights of others, or any notice challenging the validity, scope, or enforceability of the Intellectual Property or the Company’s or any of its subsidiaries’ Intellectual Property rights, except in each case as would
not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Other than as set forth in the Time of Sale Memorandum and the Final Memorandum, no party has, to the knowledge of the Company, infringed,
misappropriated or otherwise violated any Intellectual Property owned by the Company or any of its subsidiaries, except in each case as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Other than
as described in the Time of Sale Memorandum and the Final Memorandum, all Intellectual Property owned by the Company or its subsidiaries is owned solely by the Company or its subsidiaries and is owned free and clear of all liens, encumbrances,
defects or other restrictions, except in each case as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. All licenses pursuant to which any third party Intellectual Property is licensed by the
Company or its subsidiaries are free of any restrictions that would conflict with the conduct of the business of the Company or any of its subsidiaries. To the knowledge of the 

  
 10 








 
Company, all Intellectual Property owned or licensed by the Company is valid and enforceable except where such invalidity or unenforceability would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries is subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department,
commission, board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has the Company or any of its subsidiaries entered into or become a party to any agreement made in settlement of any pending or threatened litigation,
that materially restricts or impairs its use of any Intellectual Property. The Company and its subsidiaries have taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all material trade secrets and
confidential information owned, used or held for use by the Company or any of its subsidiaries, and no such trade secrets or confidential information have been disclosed other than to employees, representatives and agents of the Company or any of
its subsidiaries, or third parties who are bound by written confidentiality agreements. All founders, key employees and other employees involved in the development of Intellectual Property for the Company or any of its subsidiaries have signed
confidentiality and invention assignment agreements with the Company. 
 (gg)    The Company and its
subsidiaries have complied, and are presently in compliance, in all material respects, with its privacy policies and other legal obligations regarding the collection, use, transfer, storage, protection, disposal and disclosure by the Company and its
subsidiaries of personally identifiable information. 
 (hh)    Each employee benefit plan, within the
meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any organization which is a member of a
controlled group of corporations within the meaning of Section 414 of the Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”) has been maintained in compliance with
its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to, ERISA and the Code, except for noncompliance that could not reasonably be expected to have a Material Adverse Effect. 

(ii)    The Company and its subsidiaries possess all licenses, permits, certificates and other
authorizations from, and have made all declarations and filings with, all governmental authorities, required or necessary to own or lease, as the case may be, and to operate their respective properties and to carry on their respective businesses as
now or proposed to be conducted as set forth in the Time of Sale Memorandum and the Final Memorandum (“Permits”), except where the failure to obtain such Permits would not individually or in the aggregate have a Material Adverse
Effect. 

  
 11 








 (jj)    (f) The Company and its subsidiaries have good and
marketable title to all personal property owned by them (other than with respect to Intellectual Property, which is addressed exclusively in subsection (gg), in each case free and clear of all liens, encumbrances and defects except such as are
described in the Time of Sale Memorandum and the Final Memorandum or such as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and any real property and buildings held under lease by the Company
and its subsidiaries are held by them under valid, subsisting and enforceable leases (subject to the effects of bankruptcy, insolvency, fraudulent conveyance, moratorium and other similar laws relating to the rights or remedies of creditors and the
application of general principles of equity) with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries. 

(kk)    The Company and each of its subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are, in the Company’s reasonable judgment, prudent and customary in the businesses in which they are engaged; and neither the Company nor any of its subsidiaries has any reason
to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not be reasonably
likely to result in a material adverse effect on the current or future financial position, stockholders’ equity or results of operations of the Company and its subsidiaries. 

(ll)    Any statistical and market-related data included in the Time of Sale Memorandum and the Final
Memorandum are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.

 (mm)    Neither the Company nor any of its subsidiaries has any securities rated by any
“nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act. 

(nn)    Neither the Company nor, to the Company’s knowledge, any controlled affiliate of the Company
has taken, nor will the Company take, directly or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the Exchange Act. 

(oo)    The Company has timely made all filings required to be made by it under the Exchange Act and the
rules and regulations promulgated thereunder. 

  
 12 








 2.    Agreements to Sell and Purchase. The Company hereby agrees to
sell to the several Initial Purchasers, and each Initial Purchaser, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the
Company the respective principal amount of Firm Securities set forth in Schedule I hereto opposite its name at a purchase price of 98.0% of the principal amount thereof (the “Purchase Price”) plus accrued interest, if any, from
March 5, 2018 to the Closing Date (as defined below). 
 On the basis of the representations and warranties contained in this
Agreement, and subject to its terms and conditions, the Company agrees to sell to the Initial Purchasers the Additional Securities, and the Initial Purchasers shall have the right to purchase, severally and not jointly, up to $60,000,000 principal
amount of Additional Securities, for the purpose of covering sales of Securities in excess of the principal amount of the Firm Securities, at the Purchase Price, plus accrued interest, if any, to the date of payment and delivery. The Representatives
may exercise this right on behalf of the Initial Purchasers in whole or from time to time in part by giving written notice not later than 13 days after the date of this Agreement. Any exercise notice shall specify the principal amount of Additional
Securities to be purchased by the Initial Purchasers and the date on which such Additional Securities are to be purchased. Each purchase date must be at least one business day after the written notice is given and may not be earlier than the closing
date for the Firm Securities nor later than ten business days after the date of such notice. Additional Securities may be purchased as provided in Section 4 solely for the purpose of covering sales of securities in excess of the number of the
Firm Securities. On each day, if any, that Additional Securities are to be purchased (an “Option Closing Date”), each Initial Purchaser agrees, severally and not jointly, to purchase the principal amount of Additional Securities
(subject to such adjustments to eliminate fractional Securities as the Representatives may determine) that bears the same proportion to the total principal amount of Additional Securities to be purchased on such Option Closing Date as the principal
amount of Firm Securities set forth in Schedule I opposite the name of such Initial Purchaser bears to the total principal amount of Firm Securities. 

3.    Terms of Offering. The Representatives have advised the Company that the Initial Purchasers will make
an offering of the Securities purchased by the Initial Purchasers hereunder as soon as practicable after this Agreement is entered into as in the Representatives’ judgment is advisable. 

4.    Payment and Delivery. Payment for the Firm Securities shall be made to the Company in Federal or other funds
immediately available in New York City against delivery of such Firm Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York City time, on March 5, 2018, or at such other time on the same or such other
date, not later than March 12, 2018, as shall be designated in writing by the Representatives. The time and date of such payment are hereinafter referred to as the “Closing Date.” 

  
 13 








 Payment for any Additional Securities shall be made to the Company in Federal or other funds
immediately available in New York City against delivery of such Additional Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York City time, on the date specified in the corresponding notice described
in Section 2 or at such other time on the same or on such other date, in any event not later than March 27, 2018, as shall be designated in writing by the Representatives. 

The Securities shall be in definitive form or global form, as specified by the Representatives, and registered in such names and in such
denominations as the Representatives shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Securities shall be delivered to the Representatives on the
Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Initial Purchasers, with any transfer taxes payable in connection with the transfer of the Securities to the Initial Purchasers duly paid, against
payment of the Purchase Price therefor plus accrued interest, if any, to the date of payment and delivery. 

5.    Conditions to the Initial Purchasers’ Obligations. The several obligations of the Initial
Purchasers to purchase and pay for the Firm Securities on the Closing Date are subject to the following conditions: 

(a)    Subsequent to the execution and delivery of this Agreement and prior to the Closing Date there shall
not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the
Time of Sale Memorandum provided to the prospective purchasers of the Securities that, in the Representatives’ judgment, is material and adverse and that makes it, in the Representatives’ judgment, impracticable to market the Securities on
the terms and in the manner contemplated in the Time of Sale Memorandum. 
 (b)    The Representatives
shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the Company, to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as
of the Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. 

The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings
threatened. 
 (c)    The Representatives shall have received on the Closing Date an opinion and negative
assurance letter of Wilson Sonsini Goodrich & Rosati Professional Corporation, outside counsel for the Company, dated the Closing Date, in form and substance satisfactory to you. Such opinion shall be rendered to the Initial Purchasers at
the request of the Company and shall so state therein. 

  
 14 








 (d)    The Initial Purchasers shall have received on the
Closing Date an opinion and negative assurance letter of Goodwin Procter LLP, each dated the Closing Date and in form and substance satisfactory to the Representatives. 

(e)    The Initial Purchasers shall have received on each of the date hereof and the Closing Date a letter,
dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Initial Purchasers, from KPMG LLP, independent public accountants, containing statements and information of the type ordinarily included in
accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in or incorporated by reference into the Time of Sale Memorandum and the Final Memorandum; provided
that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date hereof. 

(f)    The “lock-up” agreements, each substantially in
the form of Exhibit A hereto, between the Representatives and the officers and directors of the Company for purposes of Section 16 of the Exchange Act relating to sales and certain other dispositions of shares of
Class A Common Stock or certain other securities, delivered to the Representatives on or before the date hereof, shall be in full force and effect on the Closing Date. 

(g)    The several obligations of the Initial Purchasers to purchase Additional Securities hereunder are
subject to the following conditions, and/or delivery to the Representatives on the applicable Option Closing Date of the following: 

(i)    subsequent to the execution and delivery of this Agreement and prior to the applicable Option
Closing Date there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole,
from that set forth in the Time of Sale Memorandum provided to the prospective purchasers of the Securities that, in the Representatives’ judgment, is material and adverse and that makes it, in the Representatives’ judgment, impracticable
to market the Securities on the terms and in the manner contemplated in the Time of Sale Memorandum; 

(ii)    a certificate, dated the Option Closing Date and signed by an executive officer of the Company,
confirming that the certificate delivered on the Closing Date pursuant to Section 5(b) hereof remains true and correct as of such Option Closing Date; 

(iii)    an opinion and negative assurance letter of Wilson Sonsini Goodrich & Rosati Professional
Corporation, outside counsel for the Company, dated the Option Closing Date, relating to the Additional Securities to be purchased on such Option Closing Date and otherwise to the same effect as the opinion and negative assurance letter required by
Section 5(c) hereof; 

  
 15 








 (iv)    an opinion and negative assurance letter of Goodwin
Procter LLP, counsel for the Initial Purchasers, dated the Option Closing Date, relating to the Additional Securities to be purchased on such Option Closing Date and otherwise to the same effect as the opinion and negative assurance letter required
by Section 5(d) hereof; 
 (v)    a letter dated the Option Closing Date, in form and substance
satisfactory to the Initial Purchasers, from KPMG LLP, independent public accountants, substantially in the same form and substance as the letter furnished to the Initial Purchasers pursuant to Section 5(e) hereof; provided that the
letter delivered on the Option Closing Date shall use a “cut-off date” not earlier than three business days prior to such Option Closing Date; and 

(vi)    such other documents as the Representatives may reasonably request with respect to the good
standing of the Company, the due authorization, execution and authentication of the Additional Securities to be sold on such Option Closing Date and other matters related to the execution and authentication of such Additional Securities. 

(h)    A number of shares of Class A Common Stock equal to the sum of the Maximum Number of Underlying
Securities shall have been approved for listing on the New York Stock Exchange, subject to official notice of issuance. 

6.    Covenants of the Company. The Company covenants with each Initial Purchaser as follows: 

(a)    To furnish to the Representatives in New York City, without charge, prior to 10:00 a.m. New
York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section 6(d) or (e), as many copies of the Time of Sale Memorandum, the Final Memorandum, any documents incorporated by reference
therein and any supplements and amendments thereto as the Representatives may reasonably request. 

(b)    Prior to the completion of the distribution of the Securities, before amending or supplementing the
Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to use any such proposed amendment or supplement to which the Representatives
reasonably object. 
 (c)    To furnish to the Representatives a copy of each proposed Additional Written
Offering Communication to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed Additional Written Offering Communication to which the Representatives reasonably object. 

  
 16 








 (d)    If the Time of Sale Memorandum is being used to
solicit offers to buy the Securities at a time prior to the completion of the distribution of the Securities and when the Final Memorandum is not yet available to prospective purchasers and any event shall occur or condition exist as a result of
which it is necessary to amend or supplement the Time of Sale Memorandum in order to make the statements therein, in the light of the circumstances, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to
amend or supplement the Time of Sale Memorandum to comply with applicable law, forthwith to prepare and furnish, at its own expense, to the Initial Purchasers and to any dealer upon request, either amendments or supplements to the Time of Sale
Memorandum so that the statements in the Time of Sale Memorandum as so amended or supplemented will not, in the light of the circumstances when delivered to a prospective purchaser, be misleading or so that the Time of Sale Memorandum, as amended or
supplemented, will comply with applicable law. 
 (e)    If, during such period after the date hereof and
prior to the date on which all of the Securities shall have been sold by the Initial Purchasers, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Final Memorandum in order to make the
statements therein, in the light of the circumstances when the Final Memorandum is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Final Memorandum to
comply with applicable law, forthwith to prepare and furnish, at its own expense, to the Initial Purchasers, either amendments or supplements to the Final Memorandum so that the statements in the Final Memorandum as so amended or supplemented will
not, in the light of the circumstances when the Final Memorandum is delivered to a purchaser, be misleading or so that the Final Memorandum, as amended or supplemented, will comply with applicable law. 

(f)    To endeavor to qualify the Securities for offer and sale under the securities or Blue Sky laws of
such jurisdictions as the Representatives shall reasonably request; provided that in connection therewith the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction or
subject itself to taxation in any jurisdiction in which it was not otherwise subject to taxation. 

(g)    Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is
terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s counsel and the Company’s accountants in
connection with the issuance and sale of the Securities and all other fees or expenses in connection with the preparation of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, any Additional Written Offering Communication
prepared by or 

  
 17 








 
on behalf of, used by, or referred to by the Company and any amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the delivering of copies
thereof to the Initial Purchasers, in the quantities herein above specified, (ii) all costs and expenses related to the transfer and delivery of the Securities to the Initial Purchasers, including any transfer or other taxes payable thereon,
(iii) the reasonable cost of printing or producing any Blue Sky or legal investment memorandum in connection with the offer and sale of the Securities under state securities laws and all expenses in connection with the qualification of the
Securities for offer and sale under state securities laws as provided in Section 6(f) hereof, including filing fees and the reasonable and documented fees and disbursements of counsel for the Initial Purchasers in connection with such
qualification and in connection with the Blue Sky or legal investment memorandum, provided that such fees and disbursements do not exceed $10,000, (iv) any fees charged by rating agencies for the rating of the Securities, (v) the fees and
expenses, if any, incurred in connection with the listing of the Underlying Securities on the New York Stock Exchange, (vi) the costs and charges of the Trustee and any transfer agent, registrar or depositary, (vii) the cost of the
preparation, issuance and delivery of the Securities, (viii) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities,
including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with production of road show slides and graphics, fees and expenses of any consultants engaged in connection
with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road
show, (ix) the document production charges and expenses associated with printing this Agreement and (x) all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not
otherwise made in this Section. It is understood, however, that except as provided in this Section, Section 8, and the last paragraph of Section 10, the Initial Purchasers will pay all of their costs and expenses, including fees and
disbursements of their counsel, transfer taxes payable on resale of any of the Securities by them and any advertising expenses connected with any offers they may make and any travel and lodging expenses incurred by them in connection with the road
show. 
 (h)    Neither the Company nor any Affiliate will sell, offer for sale or solicit offers to buy
or otherwise negotiate in respect of any security (as defined in the Securities Act) which could be integrated with the sale of the Securities in a manner which would require the registration under the Securities Act of the Securities. 

(i)    Not to make any General Solicitation or solicit any offer to buy or offer or sell the Securities or
the Underlying Securities in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act without the Representatives’ prior written consent. 

  
 18 








 (j)    While any of the Securities or the Underlying
Securities remain “restricted securities” within the meaning of the Securities Act, to make available, upon request, to any seller of such Securities the information specified in Rule 144A(d)(4) under the Securities Act, unless the
Company is then subject to Section 13 or 15(d) of the Exchange Act. 
 (k)    During the period of
one year after the Closing Date or any Option Closing Date, if later, the Company will not be, nor will it become, an open-end investment company, unit investment trust or face-amount certificate company that
is or is required to be registered under Section 8 of the Investment Company Act. 
 (l)    During
the period of one year after the Closing Date or any Option Closing Date, if later, the Company will not, and will not permit any person that is a controlled affiliate (as defined in Rule 144 under the Securities Act) at such time (or has been a
controlled affiliate within the three months preceding such time) to, resell any of the Securities or the Underlying Securities which constitute “restricted securities” under Rule 144 that have been reacquired by any of them. 

(m)    Not to take any action prohibited by Regulation M under the Exchange Act in connection with the
distribution of the Securities contemplated hereby. 
 (n)    To effect and maintain the listing of a
number of shares of Class A Common Stock equal to the sum of the Maximum Number of Underlying Securities on the New York Stock Exchange, subject to notice of official listing. 

(o)    To reserve and keep available at all times, free of
pre-emptive rights, a number of shares of Class A Common Stock equal to the Maximum Number of Underlying Securities for the purpose of enabling the Company to satisfy all obligations to issue the
Underlying Securities upon conversion of the Securities. Between the date hereof and the Closing Date, the Company will not do or authorize any act or thing that would result in an adjustment of the Conversion Rate of the Securities. 

The Company also agrees that, without the prior written consent of the Representatives on behalf of the Initial Purchasers, it will not,
during the period ending 60 days after the date of the Final Memorandum ( the “Restricted Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Class A Common Stock or any securities convertible into or exercisable or exchangeable for Class A Common Stock or
(2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Class A Common Stock, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of Class A Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a) the sale of the Securities under this Agreement, (b) the


  
 19 








 
issuance by the Company of any shares of Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof of which the Initial Purchasers have
been advised in writing, (c) the grant of options to purchase or the issuance by the Company of Common Stock or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, in each case
pursuant to the Company’s currently existing equity compensation plans disclosed in the Time of Sale Memorandum and the Final Memorandum, (d) the establishment of a trading plan pursuant to Rule
10b5-1 under the Exchange Act for the transfer of shares of the Class A Common Stock , provided that (i) such plan does not provide for the transfer of Class A Common Stock during the
Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall include a
statement to the effect that no transfer of Class A Common Stock may be made under such plan during the Restricted Period, (e) the entry into an agreement providing for the issuance by the Company of shares of Common Stock or any security
convertible into or exercisable for shares of Common Stock in connection with the acquisition by the Company or any of its subsidiaries of the securities, business, technology, property or other assets of another person or entity or pursuant to an
employee benefit plan assumed by the Company in connection with such acquisition, and the issuance of any such securities pursuant to any such agreement, (f) the entry into any agreement providing for the issuance of shares of Common Stock or
any security convertible into or exercisable for shares of Common Stock in connection with joint ventures, commercial relationships or other strategic transactions, and the issuance of any such securities pursuant to any such agreement, or
(g) the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to the Company’s currently existing equity compensation plans that are described in
the Time of Sale Memorandum and the Final Memorandum or pursuant to any assumed employee benefit plan contemplated by clause (e); provided that in the case of clauses (e) and (f), the aggregate number of shares of Common Stock that the
Company may sell or issue or agree to sell or issue pursuant to clauses (e) and (f) shall not exceed 5% of the total number of shares of the Common Stock issued and outstanding immediately following the completion of the transactions
contemplated by this Agreement; and provided further that in the case of clauses (b), (c), (e) and (f), each recipient of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock shall (A) execute a
lock-up agreement substantially in the form of Exhibit A hereto or (B) enter into an agreement with the Company no less restrictive than the form of lock-up
agreement set forth in Exhibit A hereto with respect to transactions described in clauses (1) and (2) in the preceding sentence, in each case with respect to the remaining portion of the Restricted Period. 

7.    Offering of Securities; Restrictions on Transfer. (a)Each Initial Purchaser, severally and not jointly,
represents and warrants that such Initial Purchaser is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). Each Initial Purchaser, severally and not jointly, agrees with the Company that
(i) it will not solicit offers for, or offer or sell, such Securities by any General Solicitation, other than a permitted communication listed on Schedule II hereto, or those made with the prior written consent of the Company, or in any
manner involving a public offering within the 

  
 20 








 
meaning of Section 4(a)(2) of the Securities Act and (ii) it will offer and sell such Securities only to persons that it reasonably believes to be QIBs that, in purchasing such
Securities, are deemed to have represented and agreed as provided in the Final Memorandum under the captions “Notice to Investors” and “Transfer Restrictions”. 

(b)    The Company agrees that the Initial Purchasers may provide copies of the Preliminary Memorandum, the
Time of Sale Memorandum, the Final Memorandum and any other agreements or documents relating thereto, including without limitation, the Indenture, to Xtract Research LLC (“Xtract”), following completion of the offering, for inclusion in an
online research service sponsored by Xtract, access to which shall be restricted by Xtract to QIBs. 

8.    Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless each Initial
Purchaser, each person, if any, who controls any Initial Purchaser within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and each affiliate of any Initial Purchaser within the meaning of
Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action
or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used by, or
referred to by the Company, any General Solicitation made by the Company, any “road show” as defined in Rule 433(h) under the Securities Act (a “road show”), the Final Memorandum or any amendment or supplement thereto, or caused
by any omission or alleged omission to state therein a material fact necessary to make the statements therein in the light of the circumstances under which they were made not misleading, except insofar as such losses, claims, damages or liabilities
are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly
for use therein. 
 (b)    Each Initial Purchaser agrees, severally and not jointly, to indemnify and
hold harmless the Company, its directors, its officers and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing
indemnity from the Company to such Initial Purchaser, but only with reference to information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use in the
Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication set forth in Schedule II hereto, road show, the Final Memorandum or any amendment or supplement thereto. 

(c)    In case any proceeding (including any governmental investigation) shall be instituted involving any
person in respect of which indemnity may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) 

  
 21 








 
shall promptly notify the person against whom such indemnity may be sought (the “indemnifying party”) in writing and the indemnifying party, upon request of the indemnified
party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred and documented fees and
disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party
unless (i) the indemnifying party and the indemnified party shall have mutually agreed in writing to the retention of such counsel, (ii) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory
to the indemnified party, (iii) the indemnified party shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party, or (iv) the named
parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and
expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by Morgan
Stanley & Co. LLC, in the case of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of
such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and
third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such
indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party,
unless such settlement (x) includes an unconditional release of such indemnified party, in such form and substance reasonably satisfactory to such indemnified party, from all liability on claims that are the subject matter of such proceeding,
and (y) does not include any statements to or any admission of fault, culpability or failure to act by or on behalf of any indemnified party. 

  
 22 








 (d)    To the extent the indemnification provided for in
Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such
indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received
by the Company on the one hand and the Initial Purchasers on the other hand from the offering of the Securities or (ii) if the allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Initial Purchasers on the other hand in connection with the statements or omissions
that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Initial Purchasers on the other hand in connection with the
offering of the Securities shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Securities (before deducting expenses) received by the Company and the total discounts and commissions received by the
Initial Purchasers bear to the aggregate offering price of the Securities. The relative fault of the Company on the one hand and of the Initial Purchasers on the other hand shall be determined by reference to, among other things, whether the untrue
or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Initial Purchasers and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission. The Initial Purchasers’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective principal amount of
Securities they have purchased hereunder, and not joint. 
 (e)    The Company and the Initial Purchasers
agree that it would not be just or equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d)
shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions
of this Section 8, no Initial Purchaser shall be required to contribute any amount in excess of the amount by which the total price at which the Securities resold by it in the initial placement of such Securities were offered to investors
exceeds the amount of any damages that such Initial Purchaser has otherwise been required to pay by reason of such untrue or 

  
 23 








 
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified
party at law or in equity. 
 (f)    The indemnity and contribution provisions contained in this
Section 8 and the representations, warranties and other statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any
investigation made by or on behalf of any Initial Purchaser, any person controlling any Initial Purchaser or any affiliate of any Initial Purchaser or by or on behalf of the Company, its officers or directors or any person controlling the Company
and (iii) acceptance of and payment for any of the Securities. 
 9.    Termination. The Initial
Purchasers may terminate this Agreement by notice given by the Representatives to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially
limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii) trading of any
securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption in securities settlement, payment
or clearance services in the United States shall have occurred, (iv) any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or
escalation of hostilities, or any change in financial markets or any calamity or crisis that, in the Representatives’ judgment, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it,
in the Representatives’ judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Securities on the terms and in the manner contemplated in the Time of Sale Memorandum or the Final Memorandum. 

10.    Effectiveness; Defaulting Initial Purchasers. This Agreement shall become effective upon the execution and
delivery hereof by the parties hereto. 
 If, on the Closing Date, or an Option Closing Date, as the case may be, any one or more of the
Initial Purchasers shall fail or refuse to purchase Securities that it or they have agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but
failed or refused to purchase is not more than one-tenth of the aggregate principal amount of Securities to be purchased on such date, the other Initial Purchasers shall be obligated severally in the
proportions that the principal amount of Firm Securities set forth opposite their respective names in Schedule I bears to the aggregate principal amount of Firm Securities set forth opposite the names of all such
non-defaulting Initial Purchasers, or in such other proportions as the Representatives may specify, to purchase the Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or
refused 

  
 24 








 
to purchase on such date; provided that in no event shall the principal amount of Securities that any Initial Purchaser has agreed to purchase pursuant to this Agreement be increased
pursuant to this Section 10 by an amount in excess of one-ninth of such principal amount of Securities without the written consent of such Initial Purchaser. If, on the Closing Date any Initial Purchaser
or Initial Purchasers shall fail or refuse to purchase Firm Securities which it or they have agreed to purchase hereunder on such date and the aggregate principal amount of Securities with respect to which such default occurs is more than one-tenth of the aggregate principal amount of Firm Securities to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Firm Securities are not made
within 36 hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting Initial Purchaser or of the Company. In any such case either the Representatives or the
Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Time of Sale Memorandum, the Final Memorandum or in any other documents or arrangements may be
effected. If, on an Option Closing Date, any Initial Purchaser or Initial Purchasers shall fail or refuse to purchase Additional Securities and the aggregate principal amount of Additional Securities with respect to which such default occurs is more
than one-tenth of the aggregate principal amount of Additional Securities to be purchased on such Option Closing Date, the non-defaulting Initial Purchasers shall have
the option to (a) terminate their obligation hereunder to purchase the Additional Securities to be sold on such Option Closing Date or (b) purchase not less than the principal amount of Additional Securities that such non-defaulting Initial Purchasers would have been obligated to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Initial Purchaser from liability in
respect of any default of such Initial Purchaser under this Agreement. 
 If this Agreement shall be terminated by the Initial Purchasers,
or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this
Agreement, the Company will reimburse the Initial Purchasers or such Initial Purchasers as have so terminated this Agreement with respect to themselves, severally, for all
out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Initial Purchasers in connection with this Agreement or the
offering contemplated hereunder. 
 11.    Entire Agreement. (a) This Agreement, together with any
contemporaneous written agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Securities, represents the entire agreement between the Company and the Initial Purchasers with
respect to the preparation of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, the conduct of the offering, and the purchase and sale of the Securities. 

(b)    The Company acknowledges that in connection with the offering of the Securities: (i) the
Initial Purchasers have acted at arm’s length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii) the Initial Purchasers owe the Company only those duties and obligations set


  
 25 








 
forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement) if any, and (iii) the Initial Purchasers may have interests that differ from those of
the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Initial Purchasers arising from an alleged breach of fiduciary duty in connection with the offering of the Securities. 

12.    Counterparts. This Agreement may be signed in two or more counterparts, each of which shall be an original,
with the same effect as if the signatures thereto and hereto were upon the same instrument. 
 13.    Applicable
Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. 

14.    Headings. The headings of the sections of this Agreement have been inserted for convenience of reference
only and shall not be deemed a part of this Agreement. 
 15.    Notices. All communications hereunder shall be
in writing and effective only upon receipt and if to the Initial Purchasers shall be delivered, mailed or sent to Morgan Stanley & Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Convertible Debt Syndicate Desk,
with a copy to the Legal Department; Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Registration Department; and if to the Company shall be delivered, mailed or sent to RingCentral, Inc. 20 Davis Drive,
Belmont, California 94002, Attention: General Counsel.  

  
 26 








 
			
	Very truly yours,
	
	RINGCENTRAL, INC.
		
	By:	 	 /s/Mitesh Dhruv

	Name:	 	Mitesh Dhruv
	Title:	 	Senior Vice President and Chief Financial Officer


 Accepted as of the date hereof 

Morgan Stanley & Co. LLC 
 Goldman Sachs & Co.
LLC 
 Acting severally on behalf of themselves and the 

    several Initial Purchasers named in 

    Schedule I hereto. 
  

			
	By:	 	Morgan Stanley & Co. LLC
		
	By:	 	 /s/David Oakes

	Name:	 	David Oakes
	Title:	 	Managing Director

  

			
	By:	 	Goldman Sachs & Co. LLC
		
	By:	 	 /s/Daniel Young

	Name:	 	Daniel Young
	Title:	 	Managing Director








 SCHEDULE I 
  

					
	 Initial Purchaser
	  	Principal Amount of
Firm Securities to be
Purchased	 
	 Morgan Stanley & Co. LLC
	  	 	122,000,000	 
	 Goldman Sachs & Co. LLC
	  	 	122,000,000	 
	 Merrill Lynch, Pierce, Fenner & Smith Incorporated
	  	 	52,000,000	 
	 Deutsche Bank Securities Inc.
	  	 	52,000,000	 
	 Jefferies LLC
	  	 	28,000,000	 
	 Raymond James & Associates, Inc.
	  	 	12,000,000	 
	 Craig-Hallum Capital Group LLC
	  	 	6,000,000	 
	 Northland Securities, Inc.
	  	 	6,000,000	 
		  	  
	  
	 
	 Total:
	  	$	400,000,000	 
		  	  
	  
	 


  
 I-1 








 SCHEDULE II 

Permitted Communications 
 Time of Sale
Memorandum 
  

	1.	Preliminary Memorandum, dated February 27, 2018 

  

	2.	Pricing term sheet, dated February 28, 2018 

 Permitted Additional Written Offering Communications

 Each electronic “road show” as defined in Rule 433(h) furnished to the Initial Purchasers prior to use that the Initial Purchasers and
Company have agreed may be used in connection with the offering of the Securities 
 Pricing term sheet, dated February 28, 2018 

Permitted General Solicitations other than Permitted Additional Written Offering Communications set forth above 

None 

  
 II-1 








 EXHIBIT A 

[Form of Lock-up Agreement] 

LOCK-UP LETTER 

February     , 2018 

Morgan Stanley & Co. LLC 
 Goldman Sachs & Co.
LLC 
 As Representatives of the several Initial Purchasers 

named in Schedule I to the Purchase Agreement 

referred to below 
 c/o Morgan
Stanley & Co. LLC 
 1585 BroadwayNew York, NY 10036 

c/o Goldman Sachs & Co. LLC 

200 West Street 
 New York, NY
10282-2198 
 Ladies and Gentlemen: 
 The
undersigned understands that you, as Representatives of the several Initial Purchasers (as defined below), propose to enter into a Purchase Agreement (the “Purchase Agreement”) with RingCentral, Inc., a Delaware corporation (the
“Company”), providing for the offering (the “Offering”) by the several Initial Purchasers named in Schedule I to the Purchase Agreement (the “Initial Purchasers”), of $300,000,000 principal amount
of convertible senior notes due 2023 of the Company (the “Securities”). The Securities will be convertible into cash, shares of the Company’s Class A common stock, par value $0.0001 per share, of the Company (the
“Common Stock”), or a combination thereof, at the Company’s option. 
 To induce the Initial Purchasers that may participate in the
Offering to continue their efforts in connection with the Offering, the undersigned hereby agrees that, without the prior written consent of Morgan Stanley & Co. LLC (“Morgan Stanley”) and Goldman Sachs & Co. LLC
(“Goldman Sachs”) on behalf of the Initial Purchasers, it will not, during the period commencing on the date hereof and ending 60 days after the date of the final offering memorandum (the “Restricted Period”)
relating to the Offering (the “Final Memorandum”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in
part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or 







 
such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a) transactions relating to shares of Common Stock or other securities acquired in open market
transactions after the completion of the Offering, provided that no filing under Section 16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired
in such open market transactions, (b) transfers of shares of Common Stock or any security convertible into Common Stock (A) as a bona fide gift, (B) to any member of the undersigned’s immediate family or to any trust for the
direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust or (C) by will or intestate
succession, or (c) distributions of shares of Common Stock or any security convertible into Common Stock to limited partners or stockholders of the undersigned, (d) if the undersigned is a corporation, partnership, limited liability
company or other business entity, transfers (A) to another corporation, partnership, limited liability company or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of
the undersigned, or to any investment fund or other entity controlled or managed by the undersigned or affiliates of the undersigned, or (B) as part of a distribution by the undersigned to its stockholders, partners, members or other
equityholders; provided that in the case of any transfer or distribution pursuant to clause (b), (c) or (d), (i) each donee or distributee shall sign and deliver a lock-up letter substantially in
the form of this letter and (ii) no filing under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the Restricted Period,
(e) the establishment or amendment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock (a “10b5-1
Plan”), provided that (i) such plan does not provide for the transfer of Common Stock during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or
voluntarily made by or on behalf of the undersigned or the Company regarding the establishment or amendment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such
plan during the Restricted Period, (f) sales of Common Stock made pursuant to a 10b5-1 Plan that has been entered into by the undersigned prior to the date of this agreement, the details of which plan
have been provided to the Initial Purchasers; provided that any Form 4 filed in connection with such transfer will indicate that the transfer was made pursuant to such 10b5-1 Plan, (g)
(A) transfers to the Company in connection with the vesting or settlement of restricted stock units or the “net” or “cashless” exercise of options or other rights to purchase shares of Common Stock for purposes of exercising
such options or rights, including any transfer for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options or rights, and (B) any transfer that would
involve a sale of any shares of Common Stock in connection with such vesting, settlement, or exercise to generate the amount of cash needed to cover the applicable exercise price, tax withholdings, or remittance payments (including estimated
amounts) due upon such event, in all such cases, pursuant to equity awards granted under a stock incentive plan or other equity award plan, which plan is described in the Company’s filings with the Securities and Exchange Commission (the
“Commission”) as of the date hereof; provided that any required filing under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that such transfer was to cover the exercise price, tax
withholding or remittance obligations of the undersigned in connection with such vesting or exercise, (h) to the Company in connection with the repurchase of shares of Common Stock issued pursuant to equity awards granted under a stock
incentive plan or other equity award plan, which plan is described in the Company’s filings with the Commission as of the date hereof, (i) transfers of Common Stock by operation of law pursuant to a qualified domestic order or in
connection with a divorce settlement, provided that each such transferee agrees to be bound in writing by the restrictions set forth herein; provided further that if the undersigned is required to


  
 2 








 
file a report under Section 16 of the Exchange Act during the Restricted Period, the undersigned shall include a statement in such report to the effect that such transfer is by operation of
law or pursuant to a qualified domestic order or in connection with a divorce settlement, as the case may be, or (j) with the prior written consent of Morgan Stanley and Goldman Sachs on behalf of the Initial Purchasers. 

In addition, the undersigned agrees that, without the prior written consent of Morgan Stanley and Goldman Sachs on behalf of the Initial
Purchasers, it will not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing
restrictions. 
 This agreement shall automatically terminate upon the earliest to occur, if any, of (a) the date the Company notifies
Morgan Stanley and Goldman Sachs prior to the execution of the Purchase Agreement, that it has determined not to proceed with the Offering, (b) the date of the termination of the Purchase Agreement if prior to the sale of any Securities
pursuant to the Purchase Agreement, or (c) March 15, 2018, if the Purchase Agreement has not been executed by that day. 
 The
undersigned understands that the Company and the Initial Purchasers are relying upon this agreement in proceeding toward consummation of the Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon
the undersigned’s heirs, legal representatives, successors and assigns. 
 Whether or not the Offering actually occurs depends on a
number of factors, including market conditions. Any Offering will only be made pursuant to a Purchase Agreement, the terms of which are subject to negotiation between the Company and the Initial Purchasers. 

 

	
	Very truly yours,
	
	  

	(Name)
	
	  

	(Address)



  
 3